Advertisement

Health Economics Review

, 1:10 | Cite as

Staff costs of hospital-based outpatient care of patients with cystic fibrosis

  • Helge HollmeyerEmail author
  • Jonas Schreyögg
  • Ulrich Wahn
  • Doris Staab
Research
  • 8.7k Downloads

Abstract

Background

This study identified per patient resource use and staff costs at a cystic fibrosis (CF) outpatient unit from the health care provider's perspective.

Methods

Personnel cost data were prospectively collected for all CF outpatients (n = 126) under routine conditions at the Charité Medical School Berlin in Germany over a six month study period. Patients were grouped according to age, sex and two severity categories. Ordinary least squares regression analysis was performed to determine the impact of various independent variables on personnel costs.

Results

The mean staff costs were €142.3 per patient over six months of outpatient service. Services provided by physicians were the biggest contributor to staff costs. Patient age correlated significantly and negatively with mean total costs per patient.

Conclusions

Age of patient is a significant determinant of staff costs for CF outpatient care. For a cost-covering remuneration of outpatient treatment it seems plausible to create separate reimbursement rates for two or three age groups and to consider additional costs due to tasks carried out by physicians without direct patient contact. The relatively low staff costs identified by our study reflect a staffing level not sufficient for specialist CF outpatient care.

Keywords

Cystic fibrosis outpatient service cost analysis micro-costing activity-based costing respiratory tract colonization lung function testing analysis of variance multivariate analysis 

Notes

Acknowledgements

We are grateful to Thomas Haustein and John Watson for critical reading of the manuscript, and we are indebted to Udo Buchholz for statistical advice.

References

  1. 1.
    Farrell PM, Rosenstein BJ, White TB, et al.: Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008,153(2):S4-S14. 10.1016/j.jpeds.2008.05.005CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sears EH, Gartman EJ, Casserly BP: Treatment options for cystic fibrosis: state of the art and future perspectives. Rev Recent Clin Trials 2011,6(2):94–107. 10.2174/157488711795177859CrossRefPubMedGoogle Scholar
  3. 3.
    Walters S: National Health Services for patients with cystic fibrosis: the good, the bad and the ugly. J R Soc Med 2002,95(Suppl 41):32–40.PubMedPubMedCentralGoogle Scholar
  4. 4.
    McCullough C, Price J: Caring for a child with cystic fibrosis: the children's nurse's role. Br J Nurs 2011,20(3):164–7.CrossRefGoogle Scholar
  5. 5.
    Cystic Fibrosis Foundation: Cystic Fibrosis Patient Registry. Annual Data Report 2008. accessed 31.05.2010 . 2010. (GENERIC) Ref Type: Internet Communication [http://www.cff.org/UploadedFiles/research/ClinicalResearch/Patient-Registry-Report-2009.pdf]Google Scholar
  6. 6.
    Dodge JA, Lewis PA, Stanton M, Wilsher J: Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J 2007,29(3):522–6. 10.1183/09031936.00099506CrossRefPubMedGoogle Scholar
  7. 7.
    Hexal - Mukoviszidose: Specialized outpatient clinics in Germany for the management of CF patients. [http://www.mukoviszidose.de/behandlung/muko.php?a=2.Website]
  8. 8.
    Johnson JA, Connolly M, Zuberbuhler P, Brown NE: Health-related quality of life for adults with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase. Pharmacotherapy 2000,20(10):1167–74. 10.1592/phco.20.15.1167.34583CrossRefPubMedGoogle Scholar
  9. 9.
    Kerem E, Conway S, Elborn S, Heijerman H: Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005,4(1):7–26. 10.1016/j.jcf.2004.12.002CrossRefPubMedGoogle Scholar
  10. 10.
    Eidt D, Mittendorf T, Wagner TO, Reimann A, Graf von der Schulenburg JM: [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany Overview of the prospective study results]. Med Klin (Munich) 2009,104(7):529–35. 10.1007/s00063-009-1112-9CrossRefGoogle Scholar
  11. 11.
    Braccini G, Festini F, Boni V, et al.: The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Chemother 2009,21(2):188–92.CrossRefGoogle Scholar
  12. 12.
    Ouyang L, Grosse SD, Amendah DD, Schechter MS: Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009,44(10):989–96. 10.1002/ppul.21090CrossRefPubMedGoogle Scholar
  13. 13.
    Huot L, Durieu I, Bourdy S, et al.: Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J Cyst Fibros 2008,7(5):403–8. 10.1016/j.jcf.2008.02.004CrossRefPubMedGoogle Scholar
  14. 14.
    Horvais V, Touzet S, Francois S, et al.: Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int J Technol Assess Health Care 2006,22(4):525–31.CrossRefGoogle Scholar
  15. 15.
    Schreyogg J, Hollmeyer H, Bluemel M, Staab D, Busse R: Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006,24(10):999–1009. 10.2165/00019053-200624100-00007CrossRefPubMedGoogle Scholar
  16. 16.
    Krauth C, Jalilvand N, Welte T, Busse R: Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003,21(14):1001–24. 10.2165/00019053-200321140-00002CrossRefPubMedGoogle Scholar
  17. 17.
    Baumann U, Stocklossa C, Greiner W, der Schulenburg JM, von der HH: Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003,2(2):84–90. CrossRefPubMedGoogle Scholar
  18. 18.
    Lieu TA, Ray GT, Farmer G, Shay GF: The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999,103(6):e72.CrossRefPubMedGoogle Scholar
  19. 19.
    Krauth C, Busse R, Smaczny C, et al.: [Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study]. Med Klin (Munich) 1999,94(10):541–8. 10.1007/BF03044951CrossRefGoogle Scholar
  20. 20.
    Johnson JA, Connolly MA, Jacobs P, Montgomery M, Brown NE, Zuberbuhler P: Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999,19(10):1159–66. 10.1592/phco.19.15.1159.30580CrossRefPubMedGoogle Scholar
  21. 21.
    Wildhagen MF, Verheij JB, Verzijl JG, et al.: Cost of care of patients with cystic fibrosis in The Netherlands in 1990–1. Thorax 1996,51(3):298–301. 10.1136/thx.51.3.298CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J: A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992,47(9):684–9. 10.1136/thx.47.9.684CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Eidt-Koch D, Wagner TO, Mittendorf T, Reimann A, der Schulenburg JM: Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany. Pediatr Pulmonol 2010.Google Scholar
  24. 24.
    Raftery J: Costing in economic evaluation. BMJ 2000,320(7249):1597. 10.1136/bmj.320.7249.1597CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Clement Nee Shrive FM, Ghali WA, Donaldson C, Manns BJ: The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches. Health Econ 2009,18(4):377–88. 10.1002/hec.1363CrossRefPubMedGoogle Scholar
  26. 26.
    Demeere N, Stouthuysen K, Roodhooft F: Time-driven activity-based costing in an outpatient clinic environment: development, relevance and managerial impact. Health Policy 2009,92(2–3):296–304. 10.1016/j.healthpol.2009.05.003CrossRefPubMedGoogle Scholar
  27. 27.
    Yereli AN: Activity-based costing and its application in a Turkish university hospital. AORN J 2009,89(3):573–91. 10.1016/j.aorn.2008.09.002CrossRefPubMedGoogle Scholar
  28. 28.
    Lin BY, Chao TH, Yao Y, et al.: How can activity-based costing methodology be performed as a powerful tool to calculate costs and secure appropriate patient care? J Med Syst 2007,31(2):85–90. 10.1007/s10916-005-9010-zCrossRefPubMedGoogle Scholar
  29. 29.
    Kaplan RS, Anderson SR: Time-driven activity-based costing. Harv Bus Rev 2004,82(11):131–8. 150PubMedGoogle Scholar
  30. 30.
    Lievens Y, van den BW, Kesteloot K: Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003,57(2):522–35. 10.1016/S0360-3016(03)00579-0CrossRefPubMedGoogle Scholar
  31. 31.
    Suthummanon S, Omachonu VK, Akcin M: Applying activity-based costing to the nuclear medicine unit. Health Serv Manage Res 2005,18(3):141–50. 10.1258/0951484054572538CrossRefPubMedGoogle Scholar
  32. 32.
    Grandlich C: Using activity-based costing in surgery. AORN J 2004,79(1):189–92. 10.1016/S0001-2092(06)61152-6CrossRefPubMedGoogle Scholar
  33. 33.
    Waters H, Abdallah H, Santillan D: Application of activity-based costing (ABC) for a Peruvian NGO healthcare provider. Int J Health Plann Manage 2001,16(1):3–18. 10.1002/hpm.606CrossRefPubMedGoogle Scholar
  34. 34.
    Dugueperoux I, Tamalet A, Sermet-Gaudelus I, et al.: Clinical changes of patients with cystic fibrosis during transition from pediatric to adult care. J Adolesc Health 2008,43(5):459–65. 10.1016/j.jadohealth.2008.03.005CrossRefPubMedGoogle Scholar
  35. 35.
    Stern M, Wiedemann B, Wenzlaff P: From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995 2006. Eur Respir J 2008,31(1):29–35. 10.1183/09031936.00056507CrossRefPubMedGoogle Scholar
  36. 36.
    Balaguer A, Gonzalez dD: Home intravenous antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2008, (3):CD001917.Google Scholar
  37. 37.
    Esmond G, Butler M, McCormack AM: Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. J Clin Nurs 2006,15(1):52–60. 10.1111/j.1365-2702.2005.01236.xCrossRefPubMedGoogle Scholar
  38. 38.
    Wolter JM, Bowler SD, Nolan PJ, McCormack JG: Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997,10(4):896–900.PubMedGoogle Scholar
  39. 39.
    Bosworth DG, Nielson DW: Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997,24(1):42–7. 10.1002/(SICI)1099-0496(199707)24:1<42::AID-PPUL7>3.0.CO;2-LCrossRefGoogle Scholar

Copyright information

© Hollmeyer et al; licensee Springer. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  • Helge Hollmeyer
    • 1
    Email author
  • Jonas Schreyögg
    • 2
  • Ulrich Wahn
    • 1
  • Doris Staab
    • 1
  1. 1.Department of Pediatric Pneumonology and ImmunologyCharité University Medicine BerlinGermany
  2. 2.Institute of Health Economics and Health Care ManagementHelmholtz Zentrum MuenchenGermany

Personalised recommendations